Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06636383 · ClinicalTrials.gov registry record
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
A clinical trial of Glycogen Storage Disease Type Ia, sponsored by Ultragenyx Pharmaceutical.
- Recruiting
- Registry status
- 140
- Enrollment target
- 19
- Study locations
NCT06636383: Recruiting study of Glycogen Storage Disease Type Ia, sponsored by Ultragenyx Pharmaceutical.
NCT06636383 is a study of Glycogen Storage Disease Type Ia that is actively recruiting participants, run by Ultragenyx Pharmaceutical. The registered enrollment target is 140 participants, above the 23-participant average among 5 other Glycogen Storage Disease Type Ia trials with a reported enrollment target (509% higher). The trial reports 19 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06636383, a study of Glycogen Storage Disease Type Ia, is actively recruiting participants, sponsored by Ultragenyx Pharmaceutical.
- RECRUITING
- Registry status
- 140 participants
- Enrollment target
- 19
- Study locations
Study Summary
The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (19)
Other
- Rigshospitalet - Copenhagen
- Universitätsklinikum Hamburg Eppendorf - Hamburg
- Istituto G Gaslini Ospedale Pediatrico IRCCS - Genoa
- Osaka City General Hospital - Osaka
- Fujita Health University Hospital - Toyoake
- Hospital Clínico Universitario de Santiago - Santiago
California
- Children's Hospital of Orange County - Orange
Colorado
- Children's Hospital Colorado - Denver
Connecticut
- University of Connecticut Health Center - Hartford
Michigan
- University of Michigan - Ann Arbor
North Carolina
- Duke University Medical Center - Durham
Ohio
- The Cleveland Clinic Foundation - Cleveland
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-11-04 |
| Est. Completion | 2036-12 |
What NCT06636383 shows while recruiting
NCT06636383 is an observational study that tracks outcomes without assigning an intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 23-participant average among 5 other Glycogen Storage Disease Type Ia trials with a reported enrollment target (509% higher).
The record links to 1 condition, with Glycogen Storage Disease Type Ia appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT06636383 lists 19 locations in 14 states (Other, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT06636383 about?
NCT06636383 is a clinical study titled "Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program". The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.
What is the current status of trial NCT06636383?
This trial is currently recruiting. The enrollment target is 140 participants. The study started on 2024-11-04. Estimated completion is 2036-12.
What conditions does trial NCT06636383 study?
This clinical trial studies the following conditions: Glycogen Storage Disease Type Ia.
What interventions are being tested in trial NCT06636383?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06636383?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06636383 being conducted?
This trial has 19 study locations across California, Colorado, Connecticut, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glycogen Storage Disease Type Ia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accuracy of Lactate Meter in GSDIa
RECRUITING
-
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
RECRUITING · Phase 1
-
Accuracy of Home Lactate Meter and Accu-chek Glucometer in Patients With Glycogen Storage Disease
RECRUITING
-
A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)
COMPLETED · Phase 3
-
Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI